Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).


Study Type: Interventional
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Estimated Enrollment: 200
Actual Study Start Date: July 3, 2014
Estimated Study Completion Date: June 30, 2025
Estimated Primary Completion Date: September 27, 2019 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Avelumab